Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Regeneron Pharmaceuticals
Biotech
Regeneron pens $2B pact for Hansoh's potential rival to Zepbound
Regeneron is paying Hansoh $80 million upfront for a phase 3-stage GLP-1/GIP agonist the companies believe can hold its own against Lilly’s Zepbound.
James Waldron
Jun 2, 2025 8:20am
Sanofi's IL-33 drug fails COPD study
May 30, 2025 5:30am
Regeneron’s $256M bid wins 23andMe bankruptcy auction
May 19, 2025 10:37am
Unity's stock tumbles after eye treatment fails to match Eylea
Mar 24, 2025 11:11am
Regeneron gene therapy restores hearing in 10 of 11 children
Feb 24, 2025 3:00pm
JPM25: Regeneron, Illumina back Truveta to sequence 10M genomes
Jan 13, 2025 10:12am
